BioMed Research International / 2022 / Article / Tab 1 / Review Article
Research Progress of Population Pharmacokinetic of Metformin Table 1 Demographics of the published population pharmacokinetic studies.
Study Site Male/female Age (year) Weight (kg) Dose regimen (mg/day) Assay Subject characteristics Type of study 2006 Charles [28 ] Australia 0/27 32 (26–43) 88 (50–150) 2000 (1000–3000) mg HPLC T2DM with late pregnancy Prospective 2008 Hong [25 ] America 3/9 56 (45-63) 89(70-127) 500 mg,5d, bid; 850,5d, bid LC/MS/MS T2DM Prospective 2012 Jung-woo [18 ] Korea 42/0 26(21-31) 69(61-78) Single oral 500 mg LC-MS/MS Healthy Prospective 2013 Yoon [22 ] South Korea 96/0 22.41(19-31) 67.74(53.1-95.6) Single oral 500 mg HPLC-UV Healthy Retrospective 2013 Duong [19 ] Australia NA A: 65 (39–86) B: 27 (19–40) C: 23 (18–47) A: 86 (53–165) B: 70 (53–103) C: 58 (41–88) A: 1,500 (250–3,000) B: 1,000 (500–2,000) C: 500 (500–1,000) HPLC-UV Healthy; T2DM A: T2DM, CKD B: Healthy C: Healthy Retrospective 2014 Goswami [20 ] America NA 46 (18-90) 86.4 (34-212) Healthy:1850/850 mg T2DM: NA NA Healthy:T2DM 102 : 133 Prospective 2016 Chitnis [26 ] America 159/177 25.0 (18–50) 64.7 (45.0–111.1) NA LC-MS Healthy Retrospective 2016 Sam [23 ] America NA 11.2 (7.7-13.5) 77 (50.5-118) 1000 mg, bid UPLC Severely obese children with insulin resistance. Prospective 2018 Choi [21 ] South Korea 36/0 23.9(20.0-42.0) 176(169.1-183.5) NA LC/MS/MS Healthy Prospective 2020 Sinnappah [27 ] Australia 3/2 70(61-82) 86(78-102) 500 mg, three times a week UPLC-MS/MS T2DM patients undergoing hemodialysis Prospective 2020 Ling [24 ] China 85/40 56 (27–83) 75 (51–113) 2000 (1000–2000) mg HPLC-UV T2DM Prospective
NA: Represents the missing value, which is not mentioned in the article; T2DM: Type2 diabetes mellitus; HPLC: High-performance liquid chromatography; CKD: Chronic kidney disease.